What is Citius Oncology, Inc.'s market cap?

Citius Oncology, Inc. (CTOR) has a market capitalization of $67.1M and trades on XNAS.

Who are Citius Oncology, Inc.'s competitors?

Citius Oncology, Inc.'s key competitors include Merck & Co., Citius Pharmaceuticals Inc. Common, Iovance Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Citius Oncology, Inc. partner with?

Citius Oncology, Inc.'s notable partners include Eisai Co., Ltd., Dr. Reddy’s Laboratories, Cardinal Health, and others.

What subsidiaries does Citius Oncology, Inc. have?

Citius Oncology, Inc.'s subsidiaries include Citius Oncology Sub.

Where is Citius Oncology, Inc. headquartered?

Citius Oncology, Inc. is headquartered in United States of America. It has been publicly traded since 2024.

CTO

Citius Oncology, Inc.

CTOR

Citius Oncology is a biopharmaceutical company specializing in the development and commercialization of targeted oncology therapies.

Market cap

$67.07M-71.2%

Net income-$42.5M-63.6%

EPS (diluted)-$0.47-27.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

May 15, 2026

Revenue$1.7MMiss by $5.3M EPS-$0.27Miss by $0.26

Read the full report

Next report

Aug 18, 2026 (in a month)

Revenue estimate$5.8M

EPS estimate-$0.04

Financials

Q2 2026

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation & ratios

Valuation

See full

Market cap$67.07M-71.2%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Competitors

By market cap

Merck & Co.$308.90B+52.1%

ImmunityBio, Inc.$9.3B+287%

Iovance Biotherapeutics, Inc.$2.0B+244%

Puma Biotechnology$402.1M+129%

Lyell Immunopharma, Inc.$354.9M+162%

Coherus BioSciences$251.4M+191%

CTO

Citius Oncology, Inc.$67.1M-80.1%

Citius Pharmaceuticals$15.4M-34.5%

By revenue growth

ImmunityBio, Inc.+352%

Iovance Biotherapeutics, Inc.+34.3%

Merck & Co.+2.9%

By net margin

Merck & Co.13.59%-13.7pp

Iovance Biotherapeutics, Inc.-123.9%+52.6pp

ImmunityBio, Inc.-606.15%+704pp

Profile

Citius Oncology is a biopharmaceutical company specializing in the development and commercialization of targeted oncology therapies. The company focuses on acquiring and advancing innovative treatments with reduced development risks, primarily through new formulations of previously approved drugs or expanded indications. Its core value proposition is centered on addressing underserved rare cancers, such as cutaneous T-cell lymphoma, using engineered protein-based therapies.

Competitive position

The company holds a specialized position in the rare non-Hodgkin lymphoma market with an FDA-approved therapy that features a differentiated dual mechanism of action.

GeographiesUnited States, Europe, South America, Middle East

Customer segmentsSpecialized Medical Providers, Cancer Treatment Centers

Business modelBiopharmaceutical R&D, Direct sales, Licensing and Royalties

SuppliersContract manufacturing organizations (cGMP facilities), Third-party clinical trial sites, Raw material suppliers

CustomersSpecialty pharmacies, Hospitals, Oncology clinics, Regional distribution partners

CountryUnited States of America

Listed2024

CEOLeonard L. Mazur

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

FilingsSEC EDGAR

Questions, answered.

What is Citius Oncology, Inc.'s market cap?: Citius Oncology, Inc. (CTOR) has a market capitalization of $67.1M and trades on XNAS.
Who are Citius Oncology, Inc.'s competitors?: Citius Oncology, Inc.'s key competitors include Merck & Co., Citius Pharmaceuticals Inc. Common, Iovance Biotherapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Citius Oncology, Inc. partner with?: Citius Oncology, Inc.'s notable partners include Eisai Co., Ltd., Dr. Reddy’s Laboratories, Cardinal Health, and others.
What subsidiaries does Citius Oncology, Inc. have?: Citius Oncology, Inc.'s subsidiaries include Citius Oncology Sub.
Where is Citius Oncology, Inc. headquartered?: Citius Oncology, Inc. is headquartered in United States of America. It has been publicly traded since 2024.